News

As on June 30, 2015, Jubilant Life Sciences had a total of 815 filings for formulations of which 389 have been approved in various regions globally. This includes

Imperial has secured £3m in funding from the Wellcome Trust Seeding Drug Discovery program to build upon the research of professor Michael Schneider, the British Heart Foundation Simon

Praxbind is indicated for patients treated with Pradaxa® (dabigatran etexilate), when reversal of the anticoagulant effects of dabigatran is needed for emergency surgery/urgent procedures or in life-threatening or

The company has received an initial investment of $10 million, with an additional $15 million due upon the achievement of certain milestones. Proceeds from the Series B financing

The study was intended to see if a combination of ganetespib and docetaxel would work better than docetaxel alone for advanced non-small cell lung adenocarcinoma. Synta halted the

China-based Yabao will co-develop Lilly’s sodium-glucose linked transporter inhibitor (SGLT1) molecule. Under the deal, Yabao secures the rights to develop and commercialize the SGLT1 compound in China, while

SV Life Sciences will manage the Dementia Discovery Fund (DDF), whose investors include the government’s Department of Health (DoH), Alzheimer’s Research UK, Biogen, GlaxoSmithKline, Johnson & Johnson, Lilly,

It will join targeted Pulse Electro Magnetic Field therapy (tPEMF) and closed-loop Transcranial Electrical Stimulation (cl-TES) as one of Rio Grande Neurosciences’ core technologies. Despite undergoing treatment with

The investment will accelerate Science 37’s development and rollout of its new operating model, which solves some of the greatest inefficiencies in conducting clinical trials. Science 37 co-founder